Previously unrecognized medical conditions identifi ed in volunteers for early phase clinical studies have signifi cant clinical and ethical implications for the participant. It is therefore crucial that the potential for unexpected diagnosis is addressed during the informed consent process. But the frequency of incidental diagnosis in healthy volunteers who attend for clinical trial screening remains unclear. To assess this we retrospectively analyzed 1,131 independent screening visits for 990 volunteers at a single academic center over a 10-year period to describe the frequency and nature of new clinical fi ndings. Overall 23 of 990 volunteers (2.3%) were excluded at screening for a newly diagnosed medical abnormality. Some clinically important conditions, such as nephrotic syndrome and familial hypercholesterolemia were identifi ed. The frequency of abnormalities was associated with increasing age in males ( p = 0.02 2 for trend) but not females ( p = 0.82). These data will assist those planning and conducting phase I/II vaccine trials in healthy volunteers, and importantly should strengthen the informed consent of future trial participants. Clin Trans Sci 2012; Volume 5: 348-350
Introduction
Healthy individuals participate in clinical trials 1 and before trial enrolment they undergo rigorous screening procedures for medical abnormalities that may render them ineligible. 1, 2 Screening can identify previously unrecognized medical conditions with clear ethical implications. 3 Conversely, obtaining information about personal health status can actually be a motivation for volunteer participation in such studies. 1 Th erefore estimates of the probability of incidental fi ndings in healthy subjects are highly relevant to the informed consent of potential participants. [1] [2] [3] In addition, although these apparently healthy volunteers may not be entirely representative of the general population, data on incidental fi ndings identifi ed at screening provide a useful snapshot of morbidity in healthy individuals in the community setting who may infrequently access health services.
Despite the importance of incidental diagnosis at clinical trial screening, the frequency and nature of these fi ndings have been largely unexplored in healthy subjects, and few data are available to guide those conducting healthy volunteer clinical trials. Here we describe the frequency and characteristics of incidental medical diagnoses in a large cohort of healthy clinical trial volunteers.
Methods

Participants and study design
Case report fi les (CRFs) of all healthy volunteers aged between 18 and 65 who were screened for participation in phase I/IIa candidate vaccine trials at the Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, between July 1999 and June 2010 were reviewed.
Details of screening procedures undertaken have been described in detail, 4 and remained consistent throughout the study period. In brief, all participants underwent comprehensive clinical evaluation by a study investigator. Hematological, biochemical, and blood-borne virus testing was performed by the local diagnostic laboratory according to validated protocols. Family practitioners were contacted (with participant consent) to corroborate medical history and previous testing. Th e lead investigator in each trial was responsible for determining the clinical signifi cance of any laboratory abnormalities with reference to the relevant clinical trial protocol and standardized laboratory reference ranges, which remained consistent throughout the study period. Th e lead investigator identifi ed clinical diagnoses in consultation with the principal trial investigator ± the local safety monitor. All volunteers excluded on medical grounds were referred to their family practitioner or an appropriate specialist.
Demographic and clinical data were extracted from CRFs and entered into an electronic database (Microsoft Excel, Microsoft , Redmond, WA, USA), and 10% of entries were crosschecked with source documents to ensure accurate transcription. We excluded from the analysis volunteers with out of range laboratory fi ndings for which the clinical signifi cance could not be determined, and volunteers with preexisting medical diagnoses that had been established before screening procedures were undertaken (i.e., reported by the volunteer or identifi ed in a report from the family practitioner).
Ethics
All trials were conducted according to the principles of Good Medical Practice and the Declaration of Helsinki. Th e Oxfordshire Research Ethics Committee (OxREC) and/or the UK Department of Health Gene Th erapy Advisory Committee (GTAC) provided ethical committee approval for all studies. All participants provided written informed consent before any study procedure being carried out. analysis was restricted to investigating associations between abnormalities as a whole and demographic factors (age and gender) and screening period, using the chi-square and chi-square test for trend for categorical variables, and the Mann-Whitney test for continuous variables. Statistical analysis was performed using GraphPad Prism (GraphPad Soft ware, Version 5.0, San Diego, CA, USA), and a two-tailed alpha value of <0.05 was considered signifi cant.
Statistical analysis
Results and Discussion
We analyzed 1,131 screening attendances for 990 healthy volunteers aged 18-65 (504 males, 483 females, 3 gender not specifi ed), identifying previously unrecognized fi ndings in 23 (2.3%) individuals (14 males, 9 females, p = 0.12, 2 ). Th ese are described in Table 1 . We excluded from the analysis 25 of 990 (2.5%) individuals with out of range laboratory abnormalities for which clinical signifi cance could not be determined from the database or from CRFs, and excluded 13 of 990 (1.3%) volunteers with previously diagnosed medical conditions. We identifi ed several clinically important diagnoses, such as nephrotic syndrome, familial hypercholesterolemia, and chronic viral hepatitis ( ). Although clinical protocols were unchanged during this period, the increase in unexpected fi ndings was temporally associated with an increase in volunteer recruitment, 5 possibly suggesting a change in the source of volunteers recruited, or alternatively an increase in the baseline morbidity of volunteers screened during this period.
As we have noted, the characteristics of this cohort might not reflect those of the general adult population, and may not be generalizable to healthy volunteer populations in other settings. Information on potential confounding factors such as ethnicity or socioeconomic status, and on the long-term outcome of the conditions identifi ed was unavailable for this analysis. However, these data represent a large cohort of individuals screened at a single academic center using uniform procedures, and are consistent with a pharmaceutical industry healthy volunteer study, 6 and with similar data from over 20 years ago. 2 More recent studies have focused on African settings with greater baseline morbidity, 7 or on incidental fi ndings during neuroimaging studies of healthy subjects, 8 but incidental clinical diagnosis in healthy subjects remains a largely unexplored area.
Th e informed consent process for healthy subjects recruited to clinical trials should always involve an indication of the probability of incidental diagnosis, together with a clear statement of the actions to be taken in response to any problems identifi ed, 9,10 not least because information on incidental diagnosis may provide a valuable opportunity for clinical intervention.
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